Kymera
degrader has potential to be first precision medicine in to target a genetically defined population profound activity in preclinical models both in single agent and combination clinical strategy in place to enable accelerated approval combinations | Kymera
Company
Deck Type
Sector
Industry
Deck date
December 2021
Slide
57 of 105
Related slides by other companies
Crocs
Investor Day
September 2021
strong growth potential clogs grow the category sandals revenue by other expand the brand comfortable casual democratic self expression picking up pace product levers as investor day | Crocs
Exscientia
Investor Presentation
November 2023
potential to avoid key class wide safety concern | Exscientia
Exscientia
Investor Presentation
March 2024
potential to avoid key class wide safety concern | Exscientia
Exscientia
Investor Presentation
October 2023
potential to avoid key class wide safety concern | Exscientia
Other recent decks by Kymera
See all presentations (7 decks)
Investor Presentation
December 2023
Investor Presentation
November 2023
Investor Presentation
August 2023
Investor Presentation
June 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io